Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
5(63%)
Results Posted
50%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
4
50%
Ph phase_1
4
50%

Phase Distribution

4

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
4(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

5

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Completed(2)
Terminated(1)

Detailed Status

Active, not recruiting4
Completed2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
5
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (50.0%)
Phase 24 (50.0%)

Trials by Status

active_not_recruiting450%
completed225%
recruiting113%
terminated113%

Recent Activity

5 active trials
Showing 5 of 8
active_not_recruitingphase_2

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

NCT04968106
recruitingphase_1

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

NCT04470024
active_not_recruitingphase_2

Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

NCT04438824
terminatedphase_1

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

NCT03522142
completedphase_1

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

NCT04370704
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04968106Phase 2

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Active Not Recruiting
NCT04470024Phase 1

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

Recruiting
NCT04438824Phase 2

Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Active Not Recruiting
NCT03522142Phase 1

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Terminated
NCT04370704Phase 1

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Completed
NCT04225039Phase 2

Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

Active Not Recruiting
NCT04580485Phase 1

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Completed
NCT04494009Phase 2

PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy

Active Not Recruiting

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8